| Autor: |
RISA TSUNEMATSU, AIKO MURAI, YUKA MIZUE, TERUFUMI KUBO, TASUKU MARIYA, RENA MORITA, KENJI MURATA, TAKAYUKI KANASEKI, TOMOHIDE TSUKAHARA, YOSHIHIKO HIROHASHI, TSUYOSHI SAITO, TOSHIHIKO TORIGOE |
| Předmět: |
|
| Zdroj: |
Cancer Genomics & Proteomics (1109-6535); Jul/Aug2024, Vol. 21 Issue 4, p414-420, 7p |
| Abstrakt: |
Background/Aim: Clear cell carcinoma is a prevalent histological type of ovarian cancer in East Asia, particularly in Japan, known for its resistance to chemotherapeutic agents and poor prognosis. ARID1A gene mutations, commonly found in ovarian clear cell carcinoma (OCCC), contribute to its pathogenesis. Recent data revealed that the ARID1A mutation is related to better outcomes of cancer immunotherapy. Thus, this study aimed to investigate the immunotherapy treatment susceptibility of OCCC bearing ARID1A mutations. Materials and Methods: Expression of ARID1A was analyzed using western blotting in ovarian cancer cell lines. OCCC cell lines JHOC-9 and RMG-V were engineered to overexpress NY-ESO-1, HLAA* 02:01, and ARID1A. Sensitivity to chemotherapy and T cell receptor-transduced T (TCR-T) cells specific for NYESO- 1 was assessed in ARID1A-restored cells compared to ARID1A-deficient wild-type cells. Results: JHOC-9 cells and RMG-V cells showed no expression of ARID1A protein. Overexpression of ARID1A in JHOC-9 and RMG-V cells did not impact sensitivity to gemcitabine. While ARID1A overexpression decreased sensitivity to cisplatin in RMG-V cells, it had no such effect in JHOC-9 cells. ARID1A overexpression reduced the reactivity of NY-ESO-1-specific TCR-T cells, as observed by the IFNγ ESLIPOT assay. Conclusion: Cancer immunotherapy is an effective approach to target ARID1A-deficient clear cell carcinoma of the ovary. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
